Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
CanSino Biologics, Inc. Class H ( (HK:6185) ) has issued an update.
CanSino Biologics Inc. has announced significant changes to its corporate governance structure, including the proposed cancellation of its Board of Supervisors and amendments to its Articles of Association and corporate governance rules. These changes aim to enhance the company’s governance standards and streamline operations, with the audit committee taking over the functions of the Board of Supervisors. The proposed changes are subject to approval by shareholders at an extraordinary general meeting.
The most recent analyst rating on (HK:6185) stock is a Hold with a HK$41.00 price target. To see the full list of analyst forecasts on CanSino Biologics, Inc. Class H stock, see the HK:6185 Stock Forecast page.
More about CanSino Biologics, Inc. Class H
CanSino Biologics Inc. is a biotechnology company based in the People’s Republic of China, primarily focused on the development and commercialization of vaccines. The company operates within the pharmaceutical industry, with a market focus on innovative vaccine products.
Average Trading Volume: 2,081,073
Technical Sentiment Signal: Buy
Current Market Cap: HK$13.13B
For a thorough assessment of 6185 stock, go to TipRanks’ Stock Analysis page.